Claris Lifesciences loses over 3%
DSIJ Intelligence / 09 Aug 2017
Pharmaceutical major Claris Lifesciences tumbled over 3% intraday on Wednesday as fallout of a report regarding observations made by US’ drug regulator.
Pharmaceutical major Claris Lifesciences tumbled over 3% intraday on Wednesday as fallout of a report regarding observations made by US’ drug regulator.
The US Food and Drug Administration (USFDA) issued 18 observations to the company’s Ahmedabad site. This was inspected between July 27 and August 4, 2017, according to a leading news agency. The company’s Ahmedabad site is an ex-Claris injectable site. The company sold its injectable business to Baxter for USD 625 million (Rs 3,984 crore).
The stock was trading lower by 3.02% at Rs 353 per share on the BSE at 1222 hours. It opened at Rs 362.10 per share and touched its intraday high and low at Rs 364.90 and Rs 345.10 per share, respectively. Its 52-week high stood at Rs 430.10 while the 52-week low was at Rs 217.30 per share.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.